



Neuren (NEU) – ASX Announcement

2 March 2023

Neuren appoints Joe Basile to board of directors

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced the appointment of Mr Joe Basile as an independent non-executive director.

Joe has held a number of executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales leadership roles in Australia and Asia. Joe has deep experience in corporate mergers and acquisitions, capital management and overseeing expansion activities across multiple countries with a sharp focus on shareholder value creation.

Neuren Chair Patrick Davies commented “Joe brings a wealth of industry and commercial experience to Neuren and I am delighted he has joined the Board at a time of great opportunity for our company as we pursue our growth plans. I’m sure we will benefit from Joe’s strong financial acumen and his experience with guiding rapidly expanding businesses to achieve their full potential.”

About Neuren

Neuren is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.

A New Drug Application for the lead compound, trofinetide, to treat Rett syndrome is under Priority Review by the US Food and Drug Administration (FDA), with a PDUFA action date of 12 March 2023. Neuren has granted an exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide in North America, while retaining all rights outside North America.

Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.

Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

Contact:

Patrick Davies, Chair: +61 417 856 764



ASX Listing Rules information

This announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.